Nimbus Therapeutics valuation, funding and investors
Nimbus Therapeutics works in precision small molecule drug discovery, based in Boston, United States. Founded in 2009, it has about 102 employees.
VALUATION · TODAY
$1.17B −14% after Growth
Range $283M – $2.91B · Grade DTODAY
+12 MO
$1.00B
$2.00B
$3.00B
2010
2012
2014
2016
2018
2020
2022
2024
2026
Seed $1.50M
Series A $24.0M
Series B $43.0M
Growth $60.0M
Growth $105M
Growth $125M
Growth $210M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY102 employees
+3%6m growth
−4%1y growth
−7%2y growth
50
100
150
Data from Jan 2021
Predicted in 1 yr $1.01B −14% vs today
Predicted next raise $197M if a round comes
Winding-down probability 28%
- Last round
- Growth · $210M · Sep 2023
- Valuation at last round
- $1.97B · implied
- Headcount
- 102 · flat
- Grade
- D
- Founded
- 2009
Nimbus Therapeutics valuation today
VCMC values Nimbus Therapeutics at $1.2B today, with a range of $283M to $2.9B and a grade of D. The valuation starts from its last funding round, a growth round in Sep 2023.
Valuation by date (222 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2009 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Feb 2009 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Mar 2009 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Apr 2009 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 May 2009 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Jun 2009 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Jul 2009 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Aug 2009 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Sep 2009 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Oct 2009 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Nov 2009 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Dec 2009 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Jan 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Feb 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Mar 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Apr 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 May 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Jun 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Jul 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Aug 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Sep 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Oct 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Nov 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Dec 2010 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Jan 2011 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Feb 2011 | $4.67M | $1.70M – $12.8M | $4.67M (0%) | before first round | – | unknown | D | 0% |
| 1 Mar 2011 | $6.00M | $3.94M – $18.3M | $12.0M (+100%) | after a round | – | unknown | C | 0% |
| 2 Mar 2011 | $6.01M | $3.94M – $18.3M | $12.0M (+100%) | after a round | – | unknown | C | 0% |
| 1 Apr 2011 | $6.36M | $3.94M – $18.3M | $12.0M (+89%) | after a round | – | unknown | C | 0% |
| 1 May 2011 | $6.74M | $3.94M – $18.3M | $12.0M (+78%) | after a round | – | unknown | C | 0% |
| 1 Jun 2011 | $7.14M | $3.94M – $18.3M | $12.0M (+68%) | after a round | – | unknown | C | 0% |
| 29 Jun 2011 | $45.7M | $32.1M – $116M | $82.1M (+80%) | after a round | – | unknown | C | 0% |
| 1 Jul 2011 | $45.8M | $32.1M – $116M | $82.1M (+79%) | after a round | – | unknown | C | 0% |
| 1 Aug 2011 | $48.2M | $32.1M – $116M | $82.1M (+70%) | after a round | – | unknown | C | 0% |
| 1 Sep 2011 | $50.6M | $32.1M – $116M | $82.1M (+62%) | after a round | – | unknown | C | 0% |
| 1 Oct 2011 | $53.1M | $32.1M – $116M | $82.1M (+54%) | after a round | – | unknown | C | 0% |
| 1 Nov 2011 | $55.8M | $32.1M – $116M | $82.1M (+47%) | after a round | – | unknown | C | 0% |
| 1 Dec 2011 | $58.6M | $32.1M – $116M | $82.1M (+40%) | after a round | – | unknown | C | 0% |
| 1 Jan 2012 | $61.6M | $32.1M – $116M | $82.1M (+33%) | after a round | – | unknown | C | 0% |
| 1 Feb 2012 | $64.7M | $32.1M – $116M | $82.1M (+27%) | after a round | – | unknown | C | 0% |
| 1 Mar 2012 | $67.8M | $32.1M – $116M | $82.1M (+21%) | after a round | – | unknown | C | 0% |
| 1 Apr 2012 | $71.3M | $32.1M – $116M | $82.1M (+15%) | after a round | – | unknown | C | 0% |
| 1 May 2012 | $74.8M | $32.1M – $116M | $82.1M (+10%) | after a round | – | unknown | C | 0% |
| 1 Jun 2012 | $78.7M | $32.1M – $116M | $82.1M (+4%) | after a round | – | unknown | C | 0% |
| 1 Jul 2012 | $82.1M | $31.9M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Aug 2012 | $82.1M | $30.3M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Sep 2012 | $82.1M | $28.8M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Oct 2012 | $82.1M | $27.4M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Nov 2012 | $82.1M | $26.1M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Dec 2012 | $82.1M | $24.8M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Jan 2013 | $82.1M | $23.6M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Feb 2013 | $82.1M | $22.4M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Mar 2013 | $82.1M | $21.4M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Apr 2013 | $82.1M | $20.4M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 May 2013 | $82.1M | $19.4M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Jun 2013 | $82.1M | $18.4M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Jul 2013 | $82.1M | $17.5M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Aug 2013 | $82.1M | $16.7M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Sep 2013 | $82.1M | $15.8M – $116M | $82.1M (0%) | after a round | – | unknown | C | 0% |
| 1 Oct 2013 | $82.1M | $15.1M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Nov 2013 | $82.1M | $14.3M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Dec 2013 | $82.1M | $13.6M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Jan 2014 | $82.1M | $13.0M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Feb 2014 | $82.1M | $12.3M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Mar 2014 | $82.1M | $11.8M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Apr 2014 | $82.1M | $11.2M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 May 2014 | $82.1M | $10.6M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Jun 2014 | $82.1M | $10.1M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Jul 2014 | $82.1M | $9.62M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Aug 2014 | $82.1M | $9.15M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Sep 2014 | $82.1M | $8.69M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Oct 2014 | $82.1M | $8.27M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Nov 2014 | $82.1M | $7.86M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Dec 2014 | $82.1M | $7.49M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Jan 2015 | $82.1M | $7.11M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Feb 2015 | $82.1M | $6.76M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 1 Mar 2015 | $82.1M | $6.46M – $116M | $82.1M (0%) | after a round | – | unknown | D | 0% |
| 19 Mar 2015 | $307M | $202M – $701M | $461M (+50%) | after a round | – | unknown | C | 0% |
| 1 Apr 2015 | $312M | $202M – $701M | $461M (+48%) | after a round | – | unknown | C | 0% |
| 1 May 2015 | $323M | $202M – $701M | $461M (+43%) | after a round | – | unknown | C | 0% |
| 1 Jun 2015 | $334M | $202M – $701M | $461M (+38%) | after a round | – | unknown | C | 0% |
| 1 Jul 2015 | $345M | $202M – $701M | $461M (+33%) | after a round | – | unknown | C | 0% |
| 1 Aug 2015 | $357M | $202M – $701M | $461M (+29%) | after a round | – | unknown | C | 0% |
| 1 Sep 2015 | $370M | $202M – $701M | $461M (+25%) | after a round | – | unknown | C | 0% |
| 1 Oct 2015 | $382M | $202M – $701M | $461M (+21%) | after a round | – | unknown | C | 0% |
| 1 Nov 2015 | $396M | $202M – $701M | $461M (+16%) | after a round | – | unknown | C | 0% |
| 1 Dec 2015 | $409M | $202M – $701M | $461M (+13%) | after a round | – | unknown | C | 0% |
| 1 Jan 2016 | $423M | $202M – $701M | $461M (+9%) | after a round | – | unknown | C | 0% |
| 1 Feb 2016 | $438M | $202M – $701M | $461M (+5%) | after a round | – | unknown | C | 0% |
| 1 Mar 2016 | $452M | $202M – $701M | $461M (+2%) | after a round | – | unknown | C | 0% |
| 1 Apr 2016 | $461M | $198M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 May 2016 | $461M | $189M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Jun 2016 | $461M | $181M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Jul 2016 | $461M | $174M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Aug 2016 | $461M | $166M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Sep 2016 | $461M | $159M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Oct 2016 | $461M | $152M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Nov 2016 | $461M | $146M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Dec 2016 | $461M | $140M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Jan 2017 | $461M | $134M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Feb 2017 | $461M | $128M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Mar 2017 | $461M | $123M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Apr 2017 | $461M | $108M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 May 2017 | $461M | $103M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Jun 2017 | $461M | $97.8M – $701M | $461M (0%) | after a round | – | unknown | C | 0% |
| 1 Jul 2017 | $461M | $93.1M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Aug 2017 | $461M | $88.5M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Sep 2017 | $461M | $84.1M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Oct 2017 | $461M | $80.1M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Nov 2017 | $461M | $76.1M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Dec 2017 | $461M | $72.4M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Jan 2018 | $461M | $68.8M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Feb 2018 | $461M | $65.4M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Mar 2018 | $461M | $62.5M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Apr 2018 | $461M | $59.4M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 May 2018 | $461M | $56.5M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Jun 2018 | $461M | $53.7M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Jul 2018 | $461M | $51.1M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Aug 2018 | $461M | $48.6M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Sep 2018 | $461M | $46.2M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Oct 2018 | $461M | $44.0M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Nov 2018 | $461M | $41.8M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Dec 2018 | $461M | $39.8M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Jan 2019 | $461M | $37.8M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Feb 2019 | $461M | $35.9M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Mar 2019 | $461M | $34.3M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Apr 2019 | $461M | $32.6M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 May 2019 | $461M | $31.0M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Jun 2019 | $461M | $29.5M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Jul 2019 | $461M | $28.1M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Aug 2019 | $461M | $26.7M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Sep 2019 | $461M | $25.4M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Oct 2019 | $461M | $24.1M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Nov 2019 | $461M | $22.9M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Dec 2019 | $461M | $21.8M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Jan 2020 | $461M | $20.8M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Feb 2020 | $461M | $20.2M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Mar 2020 | $461M | $20.2M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Apr 2020 | $461M | $20.2M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 May 2020 | $461M | $20.2M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Jun 2020 | $461M | $20.2M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Jul 2020 | $461M | $20.2M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Aug 2020 | $461M | $20.2M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Sep 2020 | $461M | $20.2M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 1 Oct 2020 | $461M | $20.2M – $701M | $461M (0%) | after a round | – | unknown | D | 0% |
| 15 Oct 2020 | $667M | $438M – $1.1B | $733M (+10%) | after a round | – | unknown | B | 0% |
| 1 Nov 2020 | $670M | $438M – $1.1B | $733M (+9%) | after a round | – | unknown | B | 0% |
| 1 Dec 2020 | $675M | $438M – $1.1B | $733M (+9%) | after a round | – | unknown | B | 0% |
| 1 Jan 2021 | $681M | $438M – $1.1B | $733M (+8%) | after a round | 43 | unknown | B | 0% |
| 1 Feb 2021 | $686M | $438M – $1.1B | $733M (+7%) | after a round | 43 | unknown | B | 0% |
| 1 Mar 2021 | $691M | $438M – $1.1B | $733M (+6%) | after a round | 43 | unknown | B | 0% |
| 1 Apr 2021 | $697M | $438M – $1.1B | $733M (+5%) | after a round | 43 | unknown | B | 0% |
| 1 May 2021 | $702M | $438M – $1.1B | $733M (+4%) | after a round | 43 | unknown | B | 0% |
| 1 Jun 2021 | $708M | $438M – $1.1B | $733M (+4%) | after a round | 43 | unknown | B | 0% |
| 1 Jul 2021 | $713M | $438M – $1.1B | $733M (+3%) | after a round | 43 | unknown | B | 0% |
| 14 Jul 2021 | $980M | $690M – $1.5B | $1.1B (+10%) | after a round | 43 | unknown | B | 0% |
| 1 Aug 2021 | $985M | $690M – $1.5B | $1.1B (+9%) | after a round | 43 | unknown | B | 0% |
| 1 Sep 2021 | $993M | $690M – $1.5B | $1.1B (+9%) | after a round | 43 | unknown | B | 0% |
| 1 Oct 2021 | $1.0B | $690M – $1.5B | $1.1B (+8%) | after a round | 43 | unknown | B | 0% |
| 1 Nov 2021 | $1.0B | $690M – $1.5B | $1.1B (+7%) | after a round | 43 | unknown | B | 0% |
| 1 Dec 2021 | $1.0B | $690M – $1.5B | $1.1B (+6%) | after a round | 43 | unknown | B | 0% |
| 1 Jan 2022 | $1.0B | $690M – $1.5B | $1.1B (+5%) | after a round | 43 | unknown | B | 0% |
| 1 Feb 2022 | $1.0B | $690M – $1.5B | $1.1B (+4%) | after a round | 43 | unknown | B | 0% |
| 1 Mar 2022 | $1.0B | $690M – $1.5B | $1.1B (+4%) | after a round | 79 | growing | B | 0% |
| 1 Apr 2022 | $1.0B | $690M – $1.5B | $1.1B (+3%) | after a round | 79 | growing | B | 0% |
| 1 May 2022 | $1.1B | $690M – $1.5B | $1.1B (+2%) | after a round | 79 | growing | B | 0% |
| 1 Jun 2022 | $1.1B | $690M – $1.5B | $1.1B (+1%) | after a round | 79 | growing | B | 0% |
| 1 Jul 2022 | $1.1B | $690M – $1.5B | $1.1B (0%) | after a round | 79 | growing | B | 0% |
| 1 Aug 2022 | $1.1B | $670M – $1.5B | $1.1B (0%) | after a round | 79 | unknown | B | 0% |
| 1 Sep 2022 | $1.1B | $636M – $1.5B | $1.1B (0%) | after a round | 79 | unknown | B | 0% |
| 13 Sep 2022 | $1.3B | $906M – $2.0B | $1.4B (+10%) | after a round | 79 | unknown | B | 0% |
| 1 Oct 2022 | $1.3B | $906M – $2.0B | $1.4B (+9%) | after a round | 79 | unknown | B | 0% |
| 1 Nov 2022 | $1.3B | $906M – $2.0B | $1.4B (+9%) | after a round | 79 | unknown | B | 0% |
| 1 Dec 2022 | $1.3B | $906M – $2.0B | $1.4B (+8%) | after a round | 79 | unknown | B | 0% |
| 1 Jan 2023 | $1.3B | $906M – $2.0B | $1.4B (+7%) | after a round | 79 | unknown | B | 0% |
| 1 Feb 2023 | $1.3B | $906M – $2.0B | $1.4B (+6%) | after a round | 98 | up | B | 0% |
| 1 Mar 2023 | $1.3B | $906M – $2.0B | $1.4B (+5%) | after a round | 98 | up | B | 0% |
| 1 Apr 2023 | $1.4B | $906M – $2.0B | $1.4B (+4%) | after a round | 98 | up | B | 0% |
| 1 May 2023 | $1.4B | $906M – $2.0B | $1.4B (+4%) | after a round | 98 | up | B | 0% |
| 1 Jun 2023 | $1.4B | $906M – $2.0B | $1.4B (+3%) | after a round | 98 | up | B | 0% |
| 1 Jul 2023 | $1.4B | $906M – $2.0B | $1.4B (+2%) | after a round | 98 | up | B | 0% |
| 1 Aug 2023 | $1.4B | $906M – $2.0B | $1.4B (+1%) | after a round | 98 | up | B | 0% |
| 1 Sep 2023 | $1.4B | $906M – $2.0B | $1.4B (0%) | after a round | 98 | unknown | B | 0% |
| 7 Sep 2023 | $2.0B | $1.4B – $3.1B | $2.2B (+10%) | after a round | 98 | unknown | B | 0% |
| 1 Oct 2023 | $2.0B | $1.4B – $3.1B | $2.2B (+9%) | after a round | 98 | unknown | B | 0% |
| 1 Nov 2023 | $2.0B | $1.4B – $3.1B | $2.2B (+8%) | after a round | 97 | flat | B | 5% |
| 1 Dec 2023 | $2.0B | $1.4B – $3.1B | $2.1B (+7%) | after a round | 97 | flat | B | 5% |
| 1 Jan 2024 | $2.0B | $1.4B – $3.1B | $2.1B (+6%) | after a round | 97 | flat | B | 5% |
| 1 Feb 2024 | $2.0B | $1.4B – $3.1B | $2.1B (+5%) | after a round | 97 | flat | B | 5% |
| 1 Mar 2024 | $2.1B | $1.4B – $3.1B | $2.2B (+4%) | after a round | 100 | flat | B | 5% |
| 1 Apr 2024 | $2.1B | $1.4B – $3.1B | $2.2B (+3%) | after a round | 100 | flat | B | 4% |
| 1 May 2024 | $2.1B | $1.4B – $3.1B | $2.2B (+3%) | after a round | 100 | flat | B | 4% |
| 1 Jun 2024 | $2.1B | $1.4B – $3.1B | $2.2B (+2%) | after a round | 100 | flat | B | 4% |
| 1 Jul 2024 | $2.1B | $1.4B – $3.1B | $2.2B (+1%) | after a round | 100 | flat | B | 3% |
| 1 Aug 2024 | $2.2B | $1.4B – $3.2B | $2.2B (0%) | after a round | 110 | up | B | 3% |
| 1 Sep 2024 | $2.2B | $1.4B – $3.2B | $2.2B (-1%) | after a round | 110 | up | B | 3% |
| 1 Oct 2024 | $2.2B | $1.4B – $3.2B | $2.2B (-1%) | after a round | 110 | up | B | 3% |
| 1 Nov 2024 | $2.2B | $1.4B – $3.2B | $2.2B (-1%) | after a round | 110 | up | B | 2% |
| 1 Dec 2024 | $2.2B | $1.3B – $3.2B | $2.2B (-1%) | after a round | 110 | up | B | 2% |
| 1 Jan 2025 | $2.2B | $1.3B – $3.2B | $2.2B (-1%) | after a round | 110 | up | B | 2% |
| 1 Feb 2025 | $2.2B | $1.2B – $3.2B | $2.2B (-1%) | after a round | 110 | up | B | 2% |
| 1 Mar 2025 | $2.2B | $1.2B – $3.2B | $2.2B (-1%) | after a round | 110 | up | B | 2% |
| 1 Apr 2025 | $2.2B | $1.2B – $3.2B | $2.2B (-1%) | after a round | 110 | up | B | 2% |
| 1 May 2025 | $2.2B | $967M – $3.2B | $2.2B (-1%) | after a round | 110 | flat | B | 1% |
| 1 Jun 2025 | $2.2B | $919M – $3.2B | $2.2B (-1%) | after a round | 110 | flat | C | 1% |
| 1 Jul 2025 | $2.2B | $874M – $3.2B | $2.2B (-1%) | after a round | 110 | flat | C | 1% |
| 1 Aug 2025 | $2.2B | $831M – $3.2B | $2.2B (0%) | after a round | 110 | flat | C | 1% |
| 1 Sep 2025 | $2.2B | $783M – $3.1B | $2.2B (0%) | after a round | 106 | flat | C | 1% |
| 1 Oct 2025 | $2.0B | $746M – $3.1B | $1.8B (-10%) | after a round | 106 | flat | C | 19% |
| 1 Nov 2025 | $2.0B | $709M – $3.1B | $1.8B (-10%) | after a round | 106 | flat | C | 19% |
| 1 Dec 2025 | $1.9B | $673M – $3.1B | $1.7B (-13%) | after a round | 105 | flat | C | 24% |
| 1 Jan 2026 | $1.9B | $640M – $3.1B | $1.6B (-14%) | after a round | 105 | flat | C | 24% |
| 1 Feb 2026 | $1.9B | $608M – $3.1B | $1.6B (-15%) | after a round | 105 | flat | C | 25% |
| 1 Mar 2026 | $1.6B | $573M – $3.1B | $1.2B (-23%) | after a round | 99 | down | C | 46% |
| 1 Apr 2026 | $1.6B | $545M – $3.1B | $1.2B (-24%) | after a round | 99 | down | C | 46% |
| 1 May 2026 | $1.5B | $519M – $3.1B | $1.2B (-24%) | after a round | 99 | down | C | 46% |
| 1 Jun 2026 | $1.6B | $495M – $3.1B | $1.2B (-24%) | after a round | 101 | flat | C | 42% |
| 1 Jul 2026 | $1.6B | $471M – $3.1B | $1.2B (-23%) | after a round | 101 | flat | C | 39% |
| 1 Aug 2026 | $1.6B | $448M – $3.1B | $1.3B (-22%) | after a round | 101 | flat | C | 36% |
| 1 Sep 2026 | $1.6B | $426M – $3.1B | $1.3B (-22%) | after a round | 101 | flat | C | 33% |
| 1 Oct 2026 | $1.6B | $406M – $2.9B | $1.3B (-17%) | after a round | 102 | flat | C | 30% |
| 24 Oct 2026 | $1.2B | $283M – $2.9B | $1.0B (-14%) | after a round | 102 | flat | D | 28% |
Key facts about Nimbus Therapeutics
- Founded
- 2009
- Headquarters
- Boston, United States
- Employees
- about 102 -4% in a year
- Total raised
- $569M
- Funding rounds
- 7
- Last round
- Growth Equity Sep 2023
Nimbus Therapeutics was founded in 2009 by Bruce Booth and Ramy Farid.
Nimbus Therapeutics funding history
Nimbus Therapeutics has 7 funding rounds on record, from Mar 2011 to Sep 2023, $569M in total. None disclosed a valuation.
Growth Equity 6 Sep 2023
Led by GV, SR One, Atlas Venture; with Bain Capital Life Sciences, BVF Partners L.P., Gates Frontier, Lightstone Ventures, Pfizer Ventures, RA Capital, SV Health Investors.
Sources: nimbustx.com, statnews.com, nimbustx.com and 2 more
$210M
Growth Equity 12 Sep 2022
Led by Bain Capital Life Sciences, SV Health Investors; with Access Biotechnology, Atlas Venture, BVF Partners L.P., Lightstone Ventures, Pfizer Ventures, RA Capital, SR One, Breakthrough Energy. Individuals: Bill Gates.
Sources: nimbustx.com, biopharmadive.com, medhealthoutlook.com
$125M
Growth Equity 13 Jul 2021
Led by BVF Partners L.P.; with RA Capital, Atlas Venture, Access Biotechnology, Commodore Capital, Logos Capital, Surveyor Capital, large alternative asset manager.
Sources: nimbustx.com, fiercebiotech.com, goodwinlaw.com
$105M
Growth Equity 14 Oct 2020
Led by RA Capital; with BVF Partners L.P..
Sources: nimbustx.com, fiercebiotech.com, goodwinlaw.com and 1 more
$60M
Series B 18 Mar 2015
Led by Pfizer Venture Investments, Lightstone Ventures; with Atlas Venture, SR One, Lilly Ventures. Individuals: Bill Gates.
Sources: nimbustx.com
$43M
Series A 28 Jun 2011
Led by Atlas Venture, SR One, Lilly Ventures.
Sources: nimbustx.com, boston.com, fiercebiotech.com and 1 more
$24M
$1.5M
Nimbus Therapeutics investors
18 investors have backed Nimbus Therapeutics; Atlas Venture, BVF Partners L.P. and RA Capital and 7 more led at least one round.
- BVF Partners L.P. lead, 4 rounds
- Bain Capital Life Sciences lead, 2 rounds
- Lilly Ventures lead, 2 rounds
- GV lead
- Pfizer Venture Investments lead
- Access Biotechnology 2 rounds
- Pfizer Ventures 2 rounds
- Breakthrough Energy
- Gates Frontier
- large alternative asset manager
- Logos Capital
- Surveyor Capital
What Nimbus Therapeutics does
Nimbus Therapeutics works in pharmaceutical products, with 13 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals.
Nimbus Therapeutics is a United States biotechnology company engaged in the development of small molecule medicines for oncology, immunology, and metabolic indications. The company specializes in computational drug design, translational medicine, and clinical development, utilizing structure-based drug discovery and machine learning-based predictive modeling. Nimbus Therapeutics also conducts preclinical research and collaborates with pharmaceutical partners to advance its pipeline of small molecule therapies.
Description from Veridion's company data.
Products and services
- Precision Small Molecule Drug Discovery
- Structure-Based Drug Design
- Computational Drug Design
- Machine Learning-Based Predictive Modeling
- Translational Medicine Research
- Oncology Medicine Development
- Immunology Medicine Development
- Metabolic Disease Medicine Development
- Clinical Trial Progression and Advancement
- Drug Candidate Preclinical Development
- Drug Candidate Clinical Development
- Strategic Partnership and Acquisition Execution
- Community Engagement Services
Markets
- Healthcare
- Biotechnology
- Pharmaceuticals
Technology
- Precision Small Molecule Design
- Computational Drug Design
- Machine Learning-Based Predictive Modeling
- Structure-Based Drug Discovery
Business model
- Business-to-Business
- Manufacturing
- Enterprise
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Nimbus Therapeutics
What is Nimbus Therapeutics worth?
Valuation $1.2B (range $283M to $2.9B), as of 24 Oct 2026.
Has Nimbus Therapeutics raised money?
Nimbus Therapeutics has 7 funding rounds on record, from Mar 2011 to Sep 2023, $569M in total. None disclosed a valuation.
Who has invested in Nimbus Therapeutics?
Atlas Venture, BVF Partners L.P., RA Capital, SR One, Lightstone Ventures and Bain Capital Life Sciences, and 12 more. Lead investors include Atlas Venture, BVF Partners L.P., RA Capital and SR One.
How many people work at Nimbus Therapeutics?
About 102, down 4% over the last year. Headcount grew from 43 in Jan 2021 to 102 in Sep 2026.
What does Nimbus Therapeutics do?
Nimbus Therapeutics works in pharmaceutical products, with 13 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals. Its main offerings are precision small molecule drug discovery, structure-based drug design and computational drug design.
When was Nimbus Therapeutics founded, and where is it based?
Nimbus Therapeutics was founded in 2009 and is based in Boston, United States. It has about 102 employees, down 4% over the last year.